Med. praxi. 2011;8(12):523-527 [Interní Med. 2010; 12(12): 579-582]

Treatment of osteoporosis - current opportunity

MUDr.Petr Hrdý, MUDr.Pavel Novosad
MEDIEKOS Labor, s. r. o., Osteocentrum Zlín

Osteoporosis is valid medical problem implicated millions fractures of sicks in the whole world. Currently indications to therapy result from

bone density measured by densitometry or result from presence of typical osteoporotic fracture in patient´s anamnesis too. Next decision-

making algorithms are detected to indicate therapy (FRAX™). Current therapy consists of non-pharmacological and pharmacological

parts, which are complemented necessarily. The pharmacological therapy can be divided into two groups on principle – anticatabolic

and osteoanabolic. Financially exacting therapy would be reserved for hardest groups of patiens with manifested osteoporosis.

Keywords: osteoporosis, raloxifene, bisphosphonates, teriparatide, parathyroid hormone, strontium ranelate, denosumab

Published: December 15, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrdý P, Novosad P. Treatment of osteoporosis - current opportunity. Med. praxi. 2011;8(12):523-527.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-4124. Go to original source... Go to PubMed...
    2. Broulík P. Osteoporóza a její léčba. Praha: Maxdorf 2009: 21.
    3. Cummings SR. LIFT study is discontinued. BMJ 2006; 332: 667. Go to original source... Go to PubMed...
    4. Cummings S, San Martin J, McClung M, et al. FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765. Go to original source... Go to PubMed...
    5. Dawson-Hughes B. The role of vitamin D in fracture prevention. IBMS BoneKey 2005; 2: 6-10. Go to original source...
    6. Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005; 97: 13-9. Go to original source... Go to PubMed...
    7. Chavassieux P, Brixen K, Zerbini C, et al. Bone formation is significantly greater in women in strontium ranelate than in those on alendronate after 6 and 12 months of treatment: histomorphometric analysis from a large randomized controlled trial. European Congress on Osteoporosis and Osteoarthritis 2011, abstract P509.
    8. Kanis JA, Oden A, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18: 1033-1046. Go to original source... Go to PubMed...
    9. Kanis JA, Johanssen H, Oden A, et al. A meta-analysisof the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int. 2011; 22: 2347-2355. Go to original source... Go to PubMed...
    10. Lindsay R, Silverman SI, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285: 320-323. Go to original source... Go to PubMed...
    11. Lock CA, Lecouturier J, Mason JM, et al. Lifestyle interventions to prevent osteoporotic fractures: a systematic review. Osteoporos Int 2006; 17: 20-28. Go to original source... Go to PubMed...
    12. Lufkin EG, Wong M, Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 2001; 1: 163-185. Go to original source... Go to PubMed...
    13. Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986; 38: 3-8. Go to original source... Go to PubMed...
    14. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468. Go to original source... Go to PubMed...
    15. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporois: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816-2822. Go to original source... Go to PubMed...
    16. Rosa J. Současné přístupy k léčbě osteoporózy. Farmakoterapie 2010; Suppl.: 75-86.
    17. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333. Go to original source... Go to PubMed...
    18. Sawka AM, Boulos P, Beattie K. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2005; 16: 1461-1474. Go to original source... Go to PubMed...
    19. Woolf AD, ?kesson K. Preventing fractures in elderly people. BMJ 2003; 327: 89-95. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.